Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

In its second-quarter earnings release, Kezar Life Sciences announced that it had dropped its phase 1 solid tumor drug. The ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

Fintel reports that on October 2, 2024, HC Wainwright & Co. downgraded their outlook for Kezar Life Sciences (NasdaqCM:KZR) ...

On Thursday, Kezar Life Sciences Inc (KZR) stock saw a decline, ending the day at $0.82 which represents a decrease of $-0.07 or -7.87% from the prior close of $0.89. The stock opened at $0.86 and ...

Kezar Life Sciences, Inc. (KZR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...